How Are Tysabri-Related PML Symptoms Diagnosed in Washington?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Occupational and Pharmaceutical Exposure Concerns

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding how they relate to progressive multifocal leukoencephalopathy (PML) is critical. The established framework for diagnosing PML in patients on immunomodulatory therapies has evolved through decades of clinical research, providing clear guidelines for early detection. This page outlines the diagnostic process and risk factors specific to Washington state.

Medical Background and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Washington who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is critical. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri increases the risk of PML, and three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Clinical Presentation, Diagnosis, and Mechanistic Pathways

Healthcare professionals are advised to monitor patients on Tysabri for any new sign or symptom that may be suggestive of PML, and Tysabri dosing should be withheld immediately at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must be enrolled in this program, read the Medication Guide, understand the risks, and complete and sign the Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Tysabri is a monoclonal antibody that binds to alpha-4 integrin, inhibiting the migration of immune cells into the brain. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus, allowing reactivation and spread of the virus in the central nervous system. The resulting lytic infection of oligodendrocytes leads to demyelination and the characteristic clinical presentation of PML, which includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and seizures.

Adequacy of Warnings and Legal Implications

The prescribing information for Tysabri includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning also notes that risk factors include the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients and healthcare providers may not fully appreciate the magnitude of risk, particularly in the context of long-term therapy. The adequacy of these warnings is a central issue in legal claims, as plaintiffs may argue that the risks were not sufficiently communicated or that the benefits were overstated relative to the known dangers.

Statute of Limitations and Settlement Considerations in Washington

For patients in Washington who have developed PML after Tysabri treatment, the statute of limitations for filing a personal injury or product liability claim is generally three years from the date the injury was discovered or reasonably should have been discovered. This timeline is critical because PML can have a delayed onset, and symptoms may not appear until months or years after exposure. The timeline between exposure and documented harm is a key factor in determining when the statute of limitations begins to run. In Washington, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused their PML. Given the severity of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), affected patients and their families should seek legal advice promptly to preserve their rights. Settlement considerations for Tysabri-related PML claims often involve evaluating the strength of evidence linking the drug to the injury, the adequacy of warnings provided to the patient and prescribing physician, and the extent of harm suffered. Because Tysabri is available only through the TOUCH Prescribing Program, which requires documentation of risk discussion, plaintiffs may face challenges in proving that warnings were inadequate. However, the boxed warning itself acknowledges that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which may support claims for significant damages.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury or product liability claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, which may have a delayed onset, the discovery rule may apply, meaning the clock starts when the patient knew or should have known that Tysabri caused their PML. It is crucial to seek legal advice promptly.

What are the key risk factors for developing PML while on Tysabri?

The three key risk factors for Tysabri-associated PML are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Tysabri Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.